RecruitingPhase 1NCT06316076

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
RenJi Hospital
Intervention
CD19-CAR-DNT cells(biological)
Enrollment
48 enrolled
Eligibility
18-65 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

Guangdong Ruishun Biotech Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06316076 on ClinicalTrials.gov

Other trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

Additional recruiting or active studies for the same condition.

See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

← Back to all trials